Scientists identify promising new target behind treatment resistance in advanced breast cancer
· Medical Xpressedited by Sadie Harley, reviewed by Andrew Zinin
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
A new Houston Methodist-led study published in Clinical Cancer Research reports a breakthrough in understanding why some patients with metastatic breast cancer fail to respond to a common and important early-stage treatment.
Co-led by Stephen Wong, the John S. Dunn Presidential Distinguished Chair in Biomedical Engineering and professor of radiology and medicine at Houston Methodist, the study analyzed 47 patients and 109 pretreatment metastatic lesions treated with trastuzumab deruxtecan (T-DXd).
The team identified S100–RAGE signaling—a pathway that functions as a communication system within cancer cells, helping them stay alive, grow, adapt to stress and resist treatment—as a key driver of early drug resistance in tumors. As T-DXd becomes more common in early treatment for metastatic breast cancer, understanding why some tumors fail to respond has become increasingly important.
"Our study suggested that S100–RAGE signaling may indicate early resistance to this drug and that even drug combination therapies may be less effective. But the exciting part is that this pathway appears targetable," Wong said.
"Using therapeutic options to block the signaling pathway made the cancer cells sensitive to early-line treatment. In metastatic lab models, the therapeutic combination with this early treatment significantly reduced metastatic lesion number, lesion size and overall tumor burden."
According to the Centers for Disease Control and Prevention, breast cancer is the second most common cancer among women in the United States and the second leading cause of cancer death among women. Data also show that metastatic breast cancer has the lowest survival rate.
Publication details
Wenjuan Dong et al, Targetable S100-RAGE signaling mediates intrinsic trastuzumab deruxtecan resistance in metastatic breast cancer, Clinical Cancer Research (2026). DOI: 10.1158/1078-0432.ccr-25-4894
Journal information: Clinical Cancer Research
Key medical concepts
metastatic breast cancertrastuzumab deruxtecan
Clinical categories
OncologyWomen's health Provided by Houston Methodist Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Scientists identify promising new target behind treatment resistance in advanced breast cancer (2026, August 4) retrieved 4 August 2026 from https://medicalxpress.com/news/2026-08-scientists-treatment-resistance-advanced-breast.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.